Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
OTC Markets
ETFs
Canadian ETFs
US ETFs
Cryptocurrency
Currencies
Commodities
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Real Time & Level II Data
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Spectrum Pharmaceuticals Inc.
SPPI
Healthcare
Biotechnology
Spectrum Pharmaceuticals Inc operates in the healthcare sector in the United States. It is a biopharmaceutical company with a primary...
strategy comprised of acquiring developing and commercializing novel and targeted oncology therapies. Eflapegrastim and Poziotinib are it current drugs in last stage development. Eflapegrastim is a novel long-acting granulocyte colony-stimulating factor G-CSF for the treatment of chemotherapy-induced neutropenia and Poziotinib is a novel irreversible tyrosine kinase inhibitor under investigation for non-small cell lung cancer NSCLC tumors with various mutations.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:SPPI)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
Next
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 08, 2022 6:06pm
New Press Release - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spectrum Pharmaceuticals, Inc. - SPPI
New York, New York--(Newsfile Corp. - October 8, 2022) - Pomerantz LLP is investigating claims on behalf of investors ofSpectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ: SPPI). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Sep 29, 2022 9:51pm
New Press Release - SPECTRUM ALERT: Bragar Eagel & Squire, P.C. is Investigating Spectrum Pharmaceuticals, Inc. on Behalf of Spectrum Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NASDAQ: SPPI) on behalf of Spectrum stockholders. Our investigation concerns whether Spectrum has violated the...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Sep 23, 2022 7:00am
New Press Release - Spectrum Pharmaceuticals Announces Debt Financing Agreement with SLR Capital Partners with $30 Million Funded at Closing
-- Multiple tranche debt financing provides Spectrum with up to $65 million ---- Funding provides additional capital to optimize commercial launch of ROLVEDON™ ---- Cash runway extended through 2024 -- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) (“Spectrum” or the “Company”), a...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Sep 22, 2022 3:31pm
New Press Release - Spectrum Pharmaceuticals Provides Update on Poziotinib Following FDA Oncologic Drugs Advisory Committee Meeting
Spectrum Pharmaceuticals (NasdaqGS: SPPI) (“Spectrum” or the “Company”), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that the U.S. Food and Drug Administration’s (“FDA”) Oncologic Drugs Advisory Committee (“ODAC”) met to review poziotinib for the...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Sep 10, 2022 7:02am
New Press Release - Spectrum Pharmaceuticals Announces Data from Poster Presentation for Poziotinib in NSCLC Patients with G778_P780dup HER2 Exon 20 Mutations at ESMO Congress 2022
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced data from a poster presentation titled: High Activity of Poziotinib in G778_P780dup HER2 Exon 20 Insertion Mutations in Non-Small Cell Lung Cancer (NSCLC)...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Sep 09, 2022 10:50pm
New Press Release - SPECTRUM PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Spectrum Pharmaceuticals, Inc. - SPPI
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI). On August 6, 2021, the Company disclosed the receipt of a...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Sep 09, 2022 4:20pm
New Press Release - Spectrum Pharmaceuticals Receives FDA Approval for ROLVEDON(TM) (eflapegrastim-xnst) Injection
First novel Long-Acting GCSF (LA-GCSF) product approved in over 20 yearsROLVEDON™ developed using proprietary LAPSCOVERY™ technology with a differentiated molecular structure and proven safety and efficacy profileCommercial team ready to launch with product available in the fourth quarter...
read article.
(824)
•••
Chefboy69
X
Post by
Chefboy69
on Sep 06, 2022 12:39pm
PDUFA on Friday here
Buy now or miss out on profits
(824)
•••
Chefboy69
X
Post by
Chefboy69
on Sep 06, 2022 9:17am
PDUFA this week
already made a double here...in one month hoping to make a triple.... GLTA
(0)
•••
PressRelease
X
Post by
PressRelease
on Sep 05, 2022 7:01am
New Press Release - Spectrum Pharmaceuticals Announces Poster Presentation for Poziotinib in NSCLC Patients with G778_P780dup HER2 Exon 20 Mutations at the Upcoming ESMO Congress 2022
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a poster presentation titled: High Activity of Poziotinib in G778_P780dup HER2 Exon 20 Insertion Mutations in Non-Small Lung Cancer (NSCLC). The poster will be...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Aug 26, 2022 10:50pm
New Press Release - SPECTRUM PHARMACEUTICALS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Spectrum Pharmaceuticals, Inc. - SPPI
NEW ORLEANS, Aug. 26, 2022 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI). On August 6, 2021, the...
read article.
(824)
•••
Chefboy69
X
Post by
Chefboy69
on Aug 15, 2022 10:19am
okay still cheap
i am being NICE here one last time stockhouse readers
(824)
•••
Chefboy69
X
Post by
Chefboy69
on Aug 11, 2022 9:32am
one last chance
YOU SNOOZE YOU LOSE!
(824)
•••
Chefboy69
X
Post by
Chefboy69
on Aug 09, 2022 9:41am
an easy DOUBLE maybe x3
here FDA PDUFA do some DD
(824)
•••
Chefboy69
X
Post by
Chefboy69
on Aug 08, 2022 8:34am
upcoming PDFUFA here
yes a gamble but could pay off BIG GLTA
Prev
1
2
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{currentVideo.storiesTitle}}:
{{story.companySymbol}}
{{story.companySymbol}}
{{story.headline}}
< Previous bulletin
Next bulletin >
The Power Play by The Market Herald
{{currentVideo.videoCaption}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous Video
{{moreVideoText}}
Next Video >
Featured News Links
Green Metals Royalty Company: "The Perfect Junior Mining Investment?" - Read More Here
Milestone Agreement for Developing Radiology Drugs Announced
Exclusive Insights on the Precious Metals Industry and What to Expect in 2023 – Download free report